Table 1. . Summary of next-generation agents and their indications for use in the USA and Europe.
| Agent | US FDA approval | EU Commission approval |
|---|---|---|
| Carfilzomib |
Use as a single agent in the treatment of patients with relapsed MM who had been treated with at least two lines of prior therapy that included a PI and an IMiD Use in combination with lenalidomide and dexamethasone for the treatment of patients with relapsed MM who have received one to three prior lines of therapy |
Use in combination with lenalidomide and dexamethasone for the treatment of patients with relapsed MM who have received at least one prior line of therapy |
| Ixazomib |
Use in combination with lenalidomide and dexamethasone for the treatment of patients with relapsed MM who have received at least one prior therapy |
Not approved |
| Pomalidomide |
Treatment of patients with MM who have received at least two prior therapies, including lenalidomide and bortezomib, and have demonstrated disease progression on or within 60 days of completion of the last therapy |
Use in patients with relapsed MM who have received at least two prior therapies, including both lenalidomide and bortezomib, and whose disease progressed after the last treatment |
| Daratumumab |
Used for the treatment of MM patients who have received at least three lines of prior therapy |
Use in the treatment of patients with relapsed/refractory MM previously treated with a PI and an IMiD who progressed on their last therapy |
| Elotuzumab |
Use in combination with lenalidomide and dexamethasone for the treatment of patients with MM who have received one to three prior therapies |
Use in combination with lenalidomide and dexamethasone in MM patients who have had at least one prior therapy |
| Panobinostat | Use in patients with MM who have received more than or equal to two prior regimens, including bortezomib and an IMiD drug | Use in combination with bortezomib and dexamethasone for adult patients with relapsed/refractory MM following prior treatment with bortezomib and an IMiD |
IMiD: Immunomodulator; MM: Multiple myeloma; PI: Proteasome inhibitor.